RG7697/NNC0090-2746 significantly reduced HbA1c levels and body weight relative to baseline values and compared to placebo, with reductions similar to those observed in patients treated with liraglutide in the open-label arm [83]
A sensitivity analysis adjusted for timing of treatment and HbA1c showed that there was no increased risk of thyroid cancer for any of the three GLP-1 medications studied as compared to insulin
You shouldnt use Saxenda with other weight loss products, including other prescription drugs, over-the-counter drugs, and herbal preparations
How Payer Friction and Patient Drop-Off Undermine Obesity GLP-1 Uptake The GLP-1 market is experiencing unprecedented demand, yet despite its clinical promise for obesity, diabetes, and other conditions, patient behavior and friction throughout the treatment journey continue to erode its commercial potential
With continued use, GLP-1 therapy leads to a more even distribution of fat, reduced abdominal bloating, and an easier time maintaining a healthy weight
